The global biotechnology industry is projected to
continue showing a robust growth through 2008. This is in perfect accord to
2007 where the global biotechnology industry achieved path breaking levels
in tems of financing and deal making. Though this year would be an acid test
for the industry due to recession in US and European markets. Ernst &
Young reported the following key findings for the year 2007.
- American and European companies raised more than US$29.9 billion in
2007.
- In Europe the industry raised around €5.5 billion, this is an
increase of approximately 18% from €4.6 billion in the year 2006.
- Venture financing reached sclaed new heights in 2007 with investment
to the tune of US$7.5 billion.
- Globally, the net loss of the industry came down to US$2.7 billion
from US$7.4 billion in 2006.
- Revenues for global public biotechnology company rose to 8%, crossing
for the first time the US$80 billion mark.
- In United States of America, the total value of all the deals
announced for the year including m erger & acquisitions and
strategic alliances was someting very close to US$60 billion. This was
much much ahead of the figures for all previous years. The figure for
such deals in Europe was about US$34 billion.
